Organisation paid for research Program year 2025 Source: CMS Open Payments

Summit Medical Group PA

Neither a doctor nor a teaching hospital

Research payments

$916,034

207 payments

Through program year 2025, Summit Medical Group PA is reported as receiving $916,034 in research payments, across 207 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$185,463	46
2024	Research	$191,650	44
2023	Research	$225,342	36
2022	Research	$53,359	10
2021	Research	$13,421	10
2020	Research	$125,822	37
2019	Research	$120,977	24

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $192,982 52 payments
Sumitomo Pharma America, Inc. $144,209 16 payments
Boston Scientific Corporation $126,834 28 payments
Pfizer Inc. $120,554 26 payments
Takeda Pharmaceuticals U.S.A., Inc. $83,633 26 payments
Teleflex LLC $58,400 6 payments
AbbVie, Inc. $42,064 6 payments
Laborie Medical Technologies Corp. $33,263 19 payments
Exact Sciences Corporation $26,595 1 payment
Janssen Research & Development, LLC $18,950 2 payments

Studies the money was for Research payments · program years 2019–2025

A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $144,209 16 payments
Sabre $118,133 19 payments
Phase 1/2a Moda+Dara RRMM $83,633 26 payments
A Randomized Openlabel Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab Msb0010718c in Combination With Andor Following Chemotherapy in Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100 $79,441 2 payments
Tecentriq Oncology Extension Study $68,704 21 payments
Randomized Trial of Barrigel to Increase Distance Between the Rectum and Prostate Bed to Decrease Rectal Dose in Patients Receiving Moderately Hypofractionated Radiation Therapy Who Have Had Recurrence of Prostate Cancer After Prostatectomy $58,400 6 payments
Multicentric Open Label Single Arm A Study of Obinutuzumab Short Duration Infusion Sdi in Patien $49,440 12 payments
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors $31,574 3 payments
Phase 2 Study in Patients With Neoadjuvant Breast Cancer $29,607 17 payments
Pinnacle $29,051 15 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $25,060 12 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.